- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07804641
Safety and Efficacy of the Combination Therapy of Fucoidan / Fucoxanthin / L-carnitine in Patients With Diabetic Nephropathy.
The purpose of this open-label, preliminary, proof-of-concept clinical trial is to evaluate the efficacy and safety of The purpose of this open-label, preliminary, proof-of-concept clinical trial is to evaluate the efficacy and safety of The purpose of this open-label, preliminary, proof-of-concept clinical trial is to evaluate the efficacy and safety of fucoidan/fucoxanthin/L-carnitine combinaed therapy in patients with diabetic kidney disease.
Participants were randomly assigned in a 1:1 ratio to either the Treatment Group or the Control Group. The primary objective is to investigate whether fucoidan/fucoxanthin/L-carnitine/Zinc yeast combinaed therapy can significantly improve albuminuria or renal function after a treatment period of 12 weeks. Secondary outcomes include evaluating the safety profile and potential side effects of the intervention.
It is hypothesized that the intervention will show a beneficial effect on albuminuria compared to the control group. in patients withdiabetic kidney disease.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Taipei, Taiwan, 116
- Wanfang Hospital, Taipei Medical Univeristy
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Documented glycated hemoglobin (HbA1c) > 6.5% with current use of anti-diabetic medication.
- A urine albumin-to-creatinine ratio (UACR) greater than 30 mcg/mg.
Exclusion Criteria:
- Age younger than 20 years.
- Inability to understand or provide written informed consent.
- Absence of regular treatment for diabetes mellitus.
- Medication non-compliance, defined as completing less than 50% of the prescribed formula (FFL) treatment.
- Newly diagnosed glomerulonephritis during the study period.
- Loss to follow-up, defined as failure to complete all laboratory tests required for outcome assessment.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: FFL group
Participants received the marine-derived formula FFL (a combination of low-molecular-weight oligo-fucoidan, fucoxanthin-containing extract, and L-carnitine) as an adjunctive therapy to their existing standard-of-care for diabetic kidney disease.
The daily dose consisted of 4 capsules per day, delivering a total of 740 mg of oligo-fucoidan, 1200 mg of fucoxanthin, and 120 mg of L-carnitine.
The intervention was maintained for a total duration of 12 weeks while keeping their baseline anti-diabetic and renoprotective medications unchanged.
|
Combined marine-derived formulation administered orally in capsule form.
Each day, participants took 4 capsules, providing a total daily dose of 740 mg of low-molecular-weight oligo-fucoidan, 1200 mg of fucoxanthin-containing extract, and 120 mg of L-carnitine.
The intervention was used as an add-on therapy to standard diabetic kidney disease care for a total duration of 12 weeks.
|
|
Sem intervenção: Control group
Participants continued their optimized standard-of-care treatment for diabetic kidney disease (including SGLT2 inhibitors and ACEIs/ARBs) for 12 weeks.
No active capsules or placebos were administered to this group.
All baseline anti-diabetic and blood pressure medications were required to remain stable and unchanged throughout the study period.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR)
Prazo: Baseline and Week 12
|
The UACR was assessed via random spot urine collection.
The primary outcome was expressed as the ratio of the difference (end-of-trial value minus baseline value) to the baseline value, calculated using the formula: \((12-weekUACR-BaselineUACR)/BaselineUACR\) * 100%.
A negative percentage indicates a reduction in albuminuria (improvement).
|
Baseline and Week 12
|
|
Percentage Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)
Prazo: Baseline and Week 12
|
Serum creatinine was measured and eGFR was calculated using the 2021 CKD-EPI creatinine equation.
The outcome was expressed as the ratio of the difference (end-of-trial value minus baseline value) to the baseline value, calculated using the formula: \((12-weekeGFR-BaselineeGFR)/BaselineeGFR\) * 100%.
This parameter was evaluated to monitor for any acute hemodynamically-induced decline (eGFR dip) upon treatment initiation.
|
Baseline and Week 12
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage Change From Baseline in Glycated Hemoglobin (HbA1c)
Prazo: Baseline and Week 12
|
Blood samples were collected to analyze HbA1c levels for evaluating glycemic control.
The outcome was expressed as the ratio of the difference (end-of-trial value minus baseline value) to the baseline value, calculated using the formula: \((12-weekHbA1c-BaselineHbA1c)/BaselineHbA1c\) * 100%.
|
Baseline and Week 12
|
|
Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)
Prazo: Baseline and Week 12
|
Fasting lipid profiles were analyzed to evaluate lipid metabolism.
The outcome was expressed as the ratio of the difference (end-of-trial value minus baseline value) to the baseline value, calculated using the formula: \((12-weekLDL-C-BaselineLDL-C)/BaselineLDL-C\) * 100%.
|
Baseline and Week 12
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Publicações Gerais
- Chen HH, Sue YM, Chen CH, Hsu YH, Hou CC, Cheng CY, Lin SL, Tsai WL, Chen TW, Chen TH. Peroxisome proliferator-activated receptor alpha plays a crucial role in L-carnitine anti-apoptosis effect in renal tubular cells. Nephrol Dial Transplant. 2009 Oct;24(10):3042-9. doi: 10.1093/ndt/gfp258. Epub 2009 Jun 2.
- Chen YC, Cheng CY, Liu CT, Sue YM, Chen TH, Hsu YH, Hwang PA, Chen CH. Alleviative effect of fucoxanthin-containing extract from brown seaweed Laminaria japonica on renal tubular cell apoptosis through upregulating Na+/H+ exchanger NHE1 in chronic kidney disease mice. J Ethnopharmacol. 2018 Oct 5;224:391-399. doi: 10.1016/j.jep.2018.06.023. Epub 2018 Jun 18.
- Chen TH, Liu CT, Cheng CY, Sue YM, Huang NJ, Chen CH. Oligosaccharides Ameliorate Acute Kidney Injury by Alleviating Cluster of Differentiation 44-Mediated Immune Responses in Renal Tubular Cells. Nutrients. 2022 Feb 11;14(4):760. doi: 10.3390/nu14040760.
- Chen CH, Sue YM, Cheng CY, Chen YC, Liu CT, Hsu YH, Hwang PA, Huang NJ, Chen TH. Oligo-fucoidan prevents renal tubulointerstitial fibrosis by inhibiting the CD44 signal pathway. Sci Rep. 2017 Jan 18;7:40183. doi: 10.1038/srep40183.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças do Sistema Endócrino
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Distúrbios da micção
- Manifestações Urológicas
- Diabetes Mellitus
- Complicações do Diabetes
- Proteinúria
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Nefropatias Diabéticas
- Albuminúria
- fucoxanthin
Outros números de identificação do estudo
- N202409023
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .